• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk’s once-weekly diabetes injection cleared in Canada

January 9, 2018 By Sarah Faulkner

Novo NordiskHealth Canada has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection as an adjunct to diet and exercise that can help adults with Type II diabetes control their blood sugar levels.

The drug, Ozempic, is a GLP-1 receptor agonist and won FDA approval in the U.S. in December.

“Many of our patients with Type II diabetes are overweight and have elevated blood sugar levels despite lifestyle changes and current therapies,” Dr. Lawrence Leiter, a professor of medicine at the University of Toronto, said in prepared remarks. “The availability of a once-weekly injectable associated with effective glucose lowering and weight loss is a welcome addition to our treatment options.”

“Factors contributing to the increased global prevalence of Type II diabetes include an aging population, lifestyle and environmental changes leading to increases in obesity and improved survival for those living with diabetes,” Dr. Jan Hux, president and chief science officer of Diabetes Canada, added. “It is critically important that both population health and clinical approaches are applied to help prevent the onset and consequences of diabetes, including solutions designed to manage weight.”

In clinical trials, people who used Ozempic experienced statistically significant and sustained blood sugar control compared to people using medicines like once-daily insulin glargine or extended-release formualtions of exenatide.

In one 40-week trial of 1,200 patients, Ozempic succeeded in lowering glucose levels in patients with Type II diabetes and demonstrated statistically significant results compared to Eli Lilly‘s (NYSE:LLY) dulaglutide compound.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Novo Nordisk

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS